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Subcutaneous (SC) injection of pasireotide, a somatostatin analog, is approved for the 
treatment of adults with Cushing’s disease (CD) for whom pituitary surgery was unsuc-
cessful or is not an option. We highlight the symptomatic and biochemical improvement 
of six patients with recurrent CD treated with pasireotide SC at a single center for at least 
1 year. Patients were treated either through commercial use (n = 5) or through the Phase 
3 trial (n = 1; http://ClinicalTrials.gov identifier, NCT00434148; study number, B2305). 
Most patients (n =  5) were female, and the mean age at diagnosis was 35.8  years. 
All patients demonstrated biochemical control at 1 year of treatment. Three of the five 
real-world patients followed for more than 1 year remain on pasireotide SC and are con-
trolled. Two patients discontinued pasireotide SC; one patient because of persistently 
elevated urinary-free cortisol levels and gallstones, and the other because of treatment 
for an unrelated brain tumor. Symptomatic improvement varied, but all patients demon-
strated weight loss. Nausea and mild, transient injection-site reactions were the most 
frequently reported adverse events. Although glycated hemoglobin (HbA1c) increased 
after treatment initiation, four of five patients maintained HbA1c levels ≤7.0% while receiv-
ing pasireotide SC and concomitant individualized diabetes medication, if necessary. In 
patients who discontinued pasireotide SC, HbA1c levels decreased within 6 weeks. This 
report documents real-world use of pasireotide SC and indicates its effectiveness as a 
long-term treatment option for patients with CD. Although hyperglycemia was observed 
in most patients, it was managed with appropriate monitoring and treatment and was 
reversible upon discontinuation of pasireotide SC.
Keywords: pasireotide, real-world clinical experience, hyperglycemia, Cushing’s disease, recurrent Cushing’s 
disease
BaCKGRoUND
Cushing’s disease (CD) has an estimated incidence of 6.2–7.6 per million person-years in the United 
States (1) and is the most common cause of Cushing’s syndrome, accounting for nearly 70% of cases 
(2). CD is characterized by an elevation in cortisol levels caused by an adrenocorticotropic hormone 
(ACTH)-secreting pituitary adenoma (3, 4). Failure to accurately identify and treat patients with the 
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disease could lead to an increased risk of mortality and worsened 
morbidity compared with the control population. Diagnosis of 
CD may be challenging because many of the signs and symptoms 
of hypercortisolism are non-specific, and similar to common 
health conditions such as hypertension, impaired glucose toler-
ance (diabetes), obesity, and osteoporosis (3, 4).
While transsphenoidal surgical resection of the corticotroph 
tumor is the recommended first-line treatment for patients with 
CD (3–6), lifelong recurrence rates are 23–33% after initial remis-
sion (5). Results from a meta-analysis of 74 studies published 
between 1976 and 2014 showed that mean remission rates in 
patients with pituitary microadenomas and macroadenomas 
were 82.1% (median, 85.7%; range, 48.7–100%) and 62.3% 
(median, 64.1%; range, 30.8–100%), respectively (6). Mean 
recurrence rates reported in patients with microadenomas and 
macroadenomas were 11.7% (median, 10.9%; range, 0–36.4%) 
and 18.8% (median, 13.9%; range 0–59%), respectively (6). In 
addition, surgical failures, including disease persistence and 
recurrence after surgery, are more common in patients with 
macroadenomas (mean, 48.8%; median, 52.2%; range, 0–71.4%) 
than in patients with microadenomas (mean, 25%; median, 
21.2%; range, 0–55.5%) (6). Thus, in cases of postsurgical disease 
recurrence or those in which surgery is not appropriate, medical 
therapy plays an important role in the long-term management of 
CD (5–7).
Pasireotide subcutaneous (SC) injection is a somatostatin 
analog approved for the treatment of adults with CD for whom 
pituitary surgery was unsuccessful or is not an option (7). In 
a Phase 3 trial in patients with CD (http://ClinicalTrials.gov 
identifier, NCT00434148; study number B2305), treatment with 
pasireotide SC was associated with normalization of urinary-free 
cortisol (UFC) levels at 6  months in 15% of patients treated 
with a 0.6-mg twice-daily (bid) dose and 26% of patients treated 
with a 0.9-mg bid dose (8). The B2305 study also demonstrated 
significant improvements in the signs and symptoms of CD and 
reductions in pituitary tumor volume. A separate analysis of the 
data from this Phase 3 trial showed marked improvements in 
the signs and symptoms of CD during 12 months of pasireotide 
treatment while UFC levels decreased (9).
Overall, there are few reports of long-term treatment with 
pasireotide SC. Data obtained in the open-ended, open-label 
extension trial of the B2305 study showed that the mean 
decrease in the UFC level after 12 months of treatment (57.3%) 
was maintained through 24  months (62.1%), suggesting that 
the efficacy and clinical benefit of pasireotide SC are sustained 
over a longer period of time (10). A single-center study in Italy 
reported that treatment with pasireotide led to a substantial 
reduction in tumor size within 6–12  months of initiation 
in a subset of eight patients from the B2305 study (11). In a 
5-year follow-up of 16 patients who remained on treatment, 
UFC reductions and clinical improvements were found to be 
sustained (12).
Data on patients with CD in a non-research setting are limited. 
This article describes the symptomatic and biochemical responses 
of six patients with recurrent CD treated with pasireotide SC for 
at least 1 year at a single center, five of whom were treated in a 
real-world setting.
INtRoDUCtIoN
Five patients were treated with pasireotide SC for at least 1 year 
as part of standard clinical care at the Oregon Health & Science 
University, Northwest Pituitary Center, Portland, OR, USA. 
Chart review was performed to assess patient baseline character-
istics, treatment course, symptomatic and biochemical responses, 
adverse events (AEs), and the tolerability of pasireotide SC over 
time. UFC assays were performed at a single diagnostic labora-
tory using liquid chromatography-tandem mass spectrometry 
(LC-MS/MS). All glycated hemoglobin (HbA1c) analyses were 
performed using an immunochemical assay; salivary cortisol 
assays were performed at the same laboratory using enzyme-
linked immunosorbent methodology. One additional patient at 
this center was part of the B2305 study group, which was a Phase 
3, double-blind, randomized, multicenter trial that evaluated 
the control of UFC by pasireotide SC in patients with confirmed 
persistent or recurrent CD after surgery, or those with newly 
diagnosed CD who were not candidates for surgery (http://
ClinicalTrials.gov identifier, NCT00434148). The primary end-
point was normalization of UFC level. Other endpoints included 
changes in serum and salivary cortisol levels over time, changes 
in clinical signs and symptoms, quality of life, and safety. Patients 
were randomly assigned to receive pasireotide SC at doses of 0.6 
or 0.9 mg bid. This study design has been previously described in 
detail by Colao et al. (8). The Oregon Health & Science University 
institutional review board (IRB) approved both the prospective 
and the retrospective study, which included these patients and 
data analysis for this study. Written informed consent from 
individual patients in the retrospective study was waived per 
IRB protocol. Written informed consent was obtained from the 
patient in the prospective clinical trial.
Investigation
The mean age of the six study patients at diagnosis was 35.8 years, 
and most patients were female (n = 5; Table 1). The mean disease 
duration was 12  years (range, 3–25  years). The most common 
symptoms reported by patients included abnormal weight gain, 
fatigue, cushingoid face, and ecchymosis. All patients underwent 
surgery, and the median time to recurrence after surgery was 
approximately 3 years (range, 5 months–22 years). All patients had 
at least 1 elevated salivary cortisol value at the time of recurrence.
treatment
Three patients were initially treated with pasireotide SC 0.6 mg bid, 
and three patients received an initial dose of 0.3 mg bid. Dosing was 
increased to 0.9 mg bid in three patients; dosing in these patients 
was subsequently reduced to 0.6  mg bid. The dose was further 
reduced to 0.3 mg bid in two patients. Two patients were naive to 
medical treatment (one of these patients was included in the B2305 
study group), and the remaining four patients initiated pasireotide 
SC due to failure of or intolerance to other medical therapies (e.g., 
ketoconazole, mifepristone, cabergoline; Table  1). Pasireotide 
SC was used in combination with cabergoline (1.0–1.5 mg twice 
weekly) in two of the real-world setting patients. The mean duration 
of treatment in all cases was 23.6 months (range, 16–31 months). 
The average time to treatment response was 4 months.
taBLe 1 | patient information.
patient 1 patient 2 patient 3 patient 4 patient 5 patient 6
Sex F F F F F M
Age at diagnosis 45 35 38 31 45 21
MRI findings at diagnosis Not available 7 mm 6 mm Not available Not available 7–8 mm
Postsurgical time to 
recurrence, months
60 5 9 264 33 30
Medical therapies prior or in 
addition to pasireotide SC
Cabergoline started 
simultaneously
None Ketoconazole followed 
by mifepristone 
(intolerant to 
mifepristone)
Cabergoline 
without 
improvement
Ketoconazole (without 
control) followed by 
cabergoline (some 
improvement)
None (SOM230 clinical 
trial patient)
Pasireotide SC dose, mg/bid 0.3 → 0.9 → 0.6 → 0.3 0.3 → 0.6 0.6 → 0.9 → 0.6 0.6 → 0.9 → 0.6 0.3 → 0.6 → 0.3 0.6
UFC after treatment (ULN) 
[baseline UFC], μg/24 h
10 (45) [13,120] Not measureda 35 (45) [6.3]b 10.9 (45) [20.2] 10 (45) [222.2] 34 (60) [62.2]
Time to treatment response 
with pasireotide (months)
3 11 12 4 17 9
Status of pasireotide SC 
treatment
Ongoing Ongoing Ongoing Stopped 
because of new 
GBM diagnosis
Ongoing Stopped because of 
lack of biochemical 
control, gallstones, and 
pathological fracture
Total duration of treatment 
with pasireotide SC, months
25 25 22 16 23 31
Time in remission on 
pasireotide SC, months
22 11 19 16 17 Unclear
bid, twice daily; GBM, glioblastoma; MRI, magnetic resonance imaging; SC, subcutaneous; UFC, urinary-free cortisol; ULN, upper limit of normal.
aLate-night salivary cortisol levels normalized to 1.9 from 8.2 nmol/L at baseline (ULN, 4.3 nmol/L) in patient No. 2.
bInitial UFC and salivary cortisol measurements for patient No. 3 were low.
Diagnosis was confirmed based on symptoms and dexamethasone-suppressed corticotropin-releasing hormone stimulation test.
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outcome and Follow-up
All patients demonstrated biochemical and clinical control at 
1  year of treatment (e.g., Figure  1). Biochemical control was 
defined as normalization of either UFC or salivary cortisol based 
on current clinical guidelines and expert opinion publications. 
Four patients remain on pasireotide SC, three of whom are 
controlled. The remaining patient, who continues on 0.3  mg 
bid pasireotide SC therapy, had elevated salivary cortisol values 
shortly after 1  year of therapy, for which the dose was titrated 
up. Patients were monitored for 24-h UFC levels, serum cortisol, 
and ACTH, starting 1 month after the initiation of treatment and 
continuing every 3 months thereafter until cortisol levels normal-
ized. The drug dose was titrated (with pasireotide SC uptitrated 
or downtitrated by 0.3  mg bid at each step, except for patient 
No. 1, for whom the pasireotide SC dose was initially uptitrated 
by 0.6 mg bid) to maintain cortisol levels and vital signs within 
normal ranges and avoid symptoms of adrenal insufficiency.
The patient treated in the B2305 study setting (patient No. 
6) was controlled at the end of the study. However, patient No. 
6 ultimately had recurrent UFC level elevations and gallstones 
that required discontinuation of pasireotide SC after 31 months 
of treatment. Another patient (patient No. 4) discontinued pasire-
otide SC treatment due to an unrelated brain tumor diagnosis and 
began high-dose dexamethasone treatment for that condition. The 
mean duration of treatment for patients continuing on the drug 
was 15 months (range, 12–17 months), with a mean time to nor-
malization of UFC or late-night salivary cortisol levels of 6 months 
(range, 3–11 months). Specific symptomatic improvements varied 
across the six patients, but all patients demonstrated weight loss.
All patients reported nausea, and three patients experienced 
injection-site reactions. Both AEs were considered to be mild in 
severity and transient. Nausea resolved with administration of 
injections after meals. Injection-site reactions were self-limiting; 
however, pretreatment with ibuprofen and the administration of 
ice to the site prior to injection were prescribed as initial treatment. 
The average baseline HbA1c level was 5.9% (range, 4.8–7.5%), with 
increases ranging from 0.6 to 3.1% (Figure 2). Four out of the five 
real-world patients exhibited HbA1c ≤7.0% at the last visit while 
receiving pasireotide SC. One of these four patients (patient No. 
5) had a normal HbA1c reading throughout the treatment and did 
not require antidiabetic medication. Patient No. 2 was diagnosed 
with diabetes mellitus before initiating treatment with pasireotide. 
Hyperglycemia was managed in all other cases by the provision of 
concomitant and individualized medical treatment, as necessary. 
Patient No. 1 received naglitinide 60 mg three times daily (tid), 
initially with 0.9 mg of pasireotide SC; naglitinide treatment was 
discontinued after approximately 8 months and the pasireotide SC 
dose was reduced to 0.6 mg. Similar discontinuation of diabetic 
medication was observed in patient No. 4, who received glimepiride 
2 mg and sitagliptin 50 mg daily, initially with 0.6 mg of pasireotide 
SC. Patient No. 4’s HbA1c increased from 5.8 to 8.9% after initiat-
ing pasireotide treatment. This patient was then administered 
antidiabetic treatment with glimepiride 2 mg daily and sitagliptin 
50 mg daily, which reduced HbA1c levels to 6.5%. Pasireotide SC 
14,000
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FIGURe 1 | Urinary-free cortisol levels of patient No. 1 over the duration of treatment. bid, twice daily; biw, twice weekly; qd, once daily; UFC, urinary-free 
cortisol; ULN, upper limit of normal.
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was increased after 2  months to 0.9  mg. After 18  months, the 
pasireotide SC dose was reduced to 0.6 mg; after 26 months, the 
diabetic medications were discontinued. HbA1c remained stable at 
6.5% after discontinuation of antiglycemics. Patient No. 3 received 
metformin 500 mg bid and glimepiride 2 mg daily with pasireotide 
SC 0.6 mg. Metformin was increased to 1,000 mg bid to normalize 
HbA1c levels after 28 months of treatment. Patient No. 2 received 
glargine 36 U daily and aspart 12 U tid, initially with 0.3 mg pasire-
otide SC. After 8 months, metformin 1,000 mg bid was initiated 
and glargine dosing was increased to 48–50 U daily. At month 15, 
the pasireotide SC dose was increased to 0.6 mg and sitagliptin 
100 mg was taken daily; HbA1c levels remained >7%, including 
after glargine was reduced to 26 U daily.
The B2305 study patient (patient No. 6) was initially treated 
with metformin 500  mg bid, which was reduced in 1  week to 
500  mg daily, but treatment was discontinued 3  weeks after 
initial treatment when HbA1c levels were observed to be low. 
All patients received counseling regarding diet and exercise. In 
general, increases in HbA1c levels were reversible upon cessation 
of pasireotide SC.
DIsCUssIoN
This cross-sectional case series review provides the first real-
world, long-term treatment evidence of the efficacy and safety of 
pasireotide SC as a viable medical treatment option for patients 
with recurrent CD. This chart review showed biochemical control 
and overall symptomatic improvement exhibited by all patients 
that varied over the course of long-term treatment. It also supports 
previous studies in the literature that highlight the importance 
of an early diagnosis of recurrence, thus improving the chances 
of control; elevated late-night salivary cortisol levels are an early 
biochemical marker of recurrent CD (5, 13, 14). Most patients 
experienced hyperglycemia, which was controlled by prescribed 
concomitant antidiabetic medication and periodic monitoring of 
the associated changes. Two cases of pasireotide SC discontinu-
ation were neither immediate, nor directly related to treatment.
This case series provides helpful examples of the successful 
management of AEs in a clinical setting. Similar to other somato-
statin analogs and previous clinical studies, the most common AEs 
experienced by patients were gastrointestinal and were managed 
by dietary modifications and the intermittent use of antidiarrheal 
agents, such as loperamide. Results from a mechanistic study con-
ducted in healthy volunteers showed that pasireotide, independent 
of dosing, caused significant decreases in insulin levels without 
changes in hepatic or peripheral insulin sensitivity (15). In all of 
the cases presented here, hyperglycemia was promptly diagnosed 
during the early stages of treatment based on previous studies and 
guidelines for CD treatment that emphasize the monitoring of blood 
glucose and HbA1c levels (16). Blood glucose levels were adequately 
controlled in accordance with the recommendations provided in 
the literature, which include following dietary restrictions, and 
individualized medical treatment regimens (16). Hyperglycemic 
effects were reported to be reversed within 6 weeks to 4 months of 
drug discontinuation, similar to other cases in the literature (17). 
Thus, these case studies highlight in a real-world setting the overall 
safety, tolerability, and manageability associated with pasireotide 
SC treatment that has been demonstrated in clinical trials.
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FIGURe 2 | Hba1c levels of patients over the duration of treatment. bid, twice daily; HbA1c, glycated hemoglobin; tid, three times daily. aBaseline data not 
available. bMetformin 500 mg bid was prescribed before the initial HbA1c result and was stopped after 11 days when HbA1c results showed low values.
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These cases provide some indication of how pasireotide SC 
might perform in a broader patient population. They also provide 
an expanded understanding of drug interactions and outcomes 
under different scenarios, which is outside of the scope of clinical 
trial protocols. However, this study has certain limitations that 
should be considered when analyzing the impact of the outcomes. 
The analysis is retrospective and based on a limited number of 
patients compared with the large sample sizes of clinical trials. 
Another limitation to be noted is that biochemical control in 
patient No. 1 and patient No. 5 was achieved with a combination 
of pasireotide and cabergoline. Patient No. 1 began treatment with 
cabergoline 3 weeks before initiating pasireotide, and this combi-
nation therapy was continued. Thus, the concomitant treatment 
may have influenced UFC measurements and/or normalization. 
In addition, the data were obtained from a single center, whose 
treatment practices may not be reflective of those practiced by all 
clinics that treat patients with CD. Overall, these data help bridge 
the gap in knowledge between outcomes from well-defined and 
regulated clinical trials and actual clinical practice, resulting in 
broader understanding by physicians/prescribers of the potential 
medical impact of pasireotide SC.
CoNCLUDING ReMaRKs
This study addresses an unmet need for data on treatment pat-
terns with pasireotide SC in a real-world setting in patients with 
recurrent CD. Safety outcomes and manageability were consistent 
with previous observations in clinical studies. In addition, this 
is the first study to describe successful hyperglycemia manage-
ment with concomitant medication and adequate monitoring in 
a real-world practice. Correlations between dose adjustments in 
diabetic medications and pasireotide SC were also documented in 
this study. The evidence generated through these cases may assist 
in optimizing patient access and influencing treatment decisions 
by physicians, such as selecting patients who will benefit the most 
from this treatment.
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